Loading...
XSHE300705
Market cap1.18bUSD
Jan 14, Last price  
17.45CNY
1D
1.99%
1Q
-25.74%
IPO
197.56%
Name

Hunan Jiudian Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300705 chart
P/E
23.51
P/S
3.22
EPS
0.74
Div Yield, %
1.09%
Shrs. gr., 5y
8.19%
Rev. gr., 5y
27.43%
Revenues
2.69b
+15.75%
241,413,229266,489,389290,492,436376,400,199534,515,072801,375,318924,061,197978,159,1321,627,664,9422,326,215,8672,692,511,460
Net income
368m
+36.54%
25,268,02137,792,56544,642,78554,527,28168,573,37771,985,02055,065,85382,259,768204,245,777269,700,151368,260,790
CFO
431m
+60.30%
30,692,79030,107,64432,195,18355,182,57280,419,42268,233,50490,740,744149,994,591190,871,610268,988,603431,185,028
Dividend
May 24, 20240.4494 CNY/sh
Earnings
May 15, 2025

Profile

Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.
URL
http://www.hnjiudian.com/
IPO date
Oct 10, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,692,511
15.75%
2,326,216
42.92%
Cost of revenue
2,251,731
1,957,548
Unusual Expense (Income)
NOPBT
440,780
368,668
NOPBT Margin
16.37%
15.85%
Operating Taxes
33,900
20,520
Tax Rate
7.69%
5.57%
NOPAT
406,880
348,147
Net income
368,261
36.54%
269,700
32.05%
Dividends
(94,622)
(61,253)
Dividend yield
0.59%
1.84%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
51,847
84,805
Long-term debt
332,575
231,783
Deferred revenue
145,374
65,523
Other long-term liabilities
(1)
2
Net debt
(160,917)
(119,511)
Cash flow
Cash from operating activities
431,185
268,989
CAPEX
(426,818)
Cash from investing activities
(424,575)
Cash from financing activities
73,551
121,019
FCF
(65,924)
(92,688)
Balance
Cash
515,340
436,099
Long term investments
30,000
Excess cash
410,714
319,789
Stockholders' equity
1,480,551
1,096,680
Invested Capital
2,092,306
1,590,864
ROIC
22.09%
26.58%
ROCE
17.58%
19.24%
EV
Common stock shares outstanding
481,837
137,174
Price
33.23
36.75%
24.30
-3.19%
Market cap
16,011,429
380.34%
3,333,340
-59.58%
EV
15,850,511
3,213,829
EBITDA
512,256
428,363
EV/EBITDA
30.94
7.50
Interest
11,062
18,423
Interest/NOPBT
2.51%
5.00%